This paper presents a case study on the design of a robust controller for the depth of anesthesia (DoA) induced by the drug propofol. This process is represented by a linear model together with a non-parametric uncertainty description that is evaluated using a patient model bank with 20 patients undergoing sedation. By using H ∞ methods, the controller is aimed to comply with robust stability and performance specifications for the class of patient models considered. A minimization problem of sensitivity and complementary sensitivity is made to design the controller. The controller that results from this procedure is approximated by a controller with a lower order, that in turn is redesigned in discrete time for computer control application. The resulting controller is evaluated in simulations using a realistic nonlinear model of DoA.
to reach an adequate level of hypnosis. For this kind of drugs, side-effects resulting from under-or over-dosing are existent, for instance the possibility of postoperative morbidity or even mortality as a result of over-dosing, on the other way, the under-dosing that results in the patient awareness during the surgery may be harmful and may result in psychological trauma. Accurate drug delivery may be possible to obtain with automatic control systems, improving current actual clinical practice and liberating the anesthetist to concentrate on important issues that relate the patients state. Although there are automatic control systems already is use, the majority of the procedures is still performed with discontinuous bolus infusions, in an open-loop feedback system. For DoA, the level is inferred from several physiological reactions, such as the loss of eye lash reflex. Recently, the measurable BIS index [12] , a measure of the electroencephalogram signal that assesses brain wave activity to determine the level of hypnosis, provides a way to automatic feedback control for DoA together with sedative drugs, such as propofol.
The use of this kind of technologies may reduce under-or over-dose risks, the total amount of drug infused and the anesthetist workload.
Literature review
Pharmacokinetic (PK) and pharmacodynamic (PD) models for the patient response to propofol have been developed [10, 15, 6 ] based on a multi-compartmental structure, with equilibrium constants that relate the drug mass migration between compartments. The PD model for sedatives comprises a nonlinear term [8] , that relates the drug concentration in the body with the actual effect, measured by the BIS index. The administration of analgesic drugs, such as remifentanil, has been shown to interfere on the BIS index and to have a synergic interaction in the sedation effect of popofol [4] .
The automatic drug delivery of sedatives based on the BIS index, as the measured variable, has been addressed using several control strategies. Fixed-gain proportionalintegrative-derivative (PID) controllers have been developed and have provided adequate performances in the clinical environment [13, 1, 9] . Other strategies, such as model predictive control (MPC) [14] , neural network based control [11] or fuzzy logic control [16] , among others, have been applied for propofol delivery control systems.
With some surprise, due to the high levels of uncertainty involved in modeling patients behavior, in the field of anesthetics administration, robust control strategies have been rarely applied. PID control, CRONE control [5] , internal model control (IMC) [2] or predictive control [7] are the few kinds of algorithms applied to this subject with robust control techniques.
Paper contributions and organization
The variability in the patients response is related to many aspects such as age, gender, health status, or even total drug uptake or time. The variability between patient models is referred to as model uncertainty and is the major issue taken into account in this paper. Controller design in the presence of these uncertainties is approached with robust control techniques, with performance and stability specifications. In a feedback control framework, the controller is designed to deliver an adequate performance on drug administration and to be able to stabilize the class of patient models. The design problem is approached with the H ∞ control theory, imposing specifications on reference tracking, output disturbances and noise rejection. The contribution of the paper consists thus of a methodology of robust controller design for DoA and its demonstration on simulation on a realistic nonlinear model, with uncertainty characterized from patient clinical data.
The paper is organized as follows: the mathematical model that describes the patient response as a function of the drug dose input is presented in section 2, followed by the description of the control design algorithm, in section 3; robust performance and stability requirements are checked in section 4 and the conclusions are drawn in section 5.
Mathematical model
The PK/PD model used in this work is described in this section. Whereas the pharmacodynamics (PD) refers to the actual effect of the drug in the patient, as a function of its concentration, the pharmacokinetics (PK) describes the drug concentration in the tissues as a function of time and drug dose.
Pharmacokinetics
The pharmacokinetic part of the model is assumed to be described by three compartments as represented in Fig. 1 . First, the drug enters the body in the central compartment (blood, liver and brain), where the drug metabolism and elimination occurs. This compartment is connected with two other peripheral compartments, with distinct equilibrating rates: a fast equilibrating compartment (2 in Fig. 1) , that represents the distribution of the central nervous system (CNS) to the muscles and organs, and the slow equilibrating compartment (3 in Fig. 1) , that represents the drug distribution in the bones and fat tissue, with distinctly slower constant rates. The PK compartmental model, that relates the drug infusion u (ml/h) with the drug plasma concentration c p (µg/ml), can be described in the state-space form,   ṁ
where m i (µg), with i = 1, 2, 3, is the mass in the compartment i, k i j (s −1 ), with i, j = 1, 2, 3, is the equilibrium constant from the i-th to the j-th compartment and V 1 (l) is the volume of the central compartment. The irreversible elimination or biotransformation of the drug is described by k 10 .
Pharmacodynamics
An extra compartment can be added to the PK model, representing the transition from the drug plasma concentration to the drug effect concentration c e . This is a first term of the PD model that is linear and is described bẏ
where k 1e (s −1 ) is the equilibrium constant between the central and the effect-site compartments and is considered to be equal to k eo (s −1 ), that is the equilibrium constant from the effect-site compartment to a hypothetical compartment where the effect is measured and the drug leaves the body. The drug effect observed on the patient is expressed as a nonlinear function of the effect-site concentration, by
where E 0 is the baseline effect at zero concentrations, E max is the peak of the drug effect, C 50 is the concentration that yields 50 % of the maximum drug effect and γ is the steepness of the concentration-response relation. The analgesic drug has an effect that must also be taken into account in the model. Moreover, the two kinds of drug (hypnotic and analgesic) act in a synergic way. In this case, the hypnotic drug considered is propofol, whereas the analgesic drug considered is remifentanil. To distinguish the variables associated with the hypnotic model from the variables associated with the analgesic models, the super-indexs prop and remi, respectively, are added to the symbols that denote the different variables. Therefore, c prop e denotes the concentration in the effect-site compartment of propofol, and c remi e denotes the concentration in the effect-site compartment of remifentanil. The existing correlation between the effect of analgesic drugs, such as remifentanil, and the effect of hypnotic drugs, in this case propofol, is expressed in the overall effect as
where U prop and U remi are the normalized effect-site concentrations defined as
Linear PK/PD model
The PK model (1,2) and the the fist term of the PD model (3), may be described by the state-space model
where Φ is a matrix with patient dependent parameters given by
x is the state and Γ contains a factor for unit conversion of the drug dose, such as
and t is the continuous time measured in seconds. The state-space system (7) is expressed, in the Laplace transform domain, by 
The BIS derivative with respect to the increments of the effect-site concentration, η, is given by +U remi
and represents the static gain of the nonlinear term of the model, that relates the increment of the drug effect-site concentration with its effect given by the increment of the BIS index with respect to its equilibrium value. In this case study, the remifentanil dose appears in the model as a disturbance.
From (12) and (10) the linearized model, ignoring the effect of the analgesic drug, is described by
where G(s), with G(s) = F(s) η, is the transfer function that relates the patient response, measured by the BIS index, with the drug dose.
Controller design
Clinically, the level of the depth of anesthesia at which the patient should be kept at is 50, and should never be lower than 30. In this case, a feedback control system that compares the reference value, that is 50, with the measured value of the BIS index, at each instant, is considered. As shown in Fig. 2 , the controller (K) compares the value of the BIS index (y) with the desired level (r), and computes the amount of drug (u) that is required to deliver to the patient (G) in order to attain the desired level. Accordingly, the manipulated variable is the increment of the drug dose u and the measured variable is the BIS index y, that is affected by the sum of all disturbances d acting on the system and by the sensor noise signal n. Such a system is described by the closed-loop model
The transfer function from d to y is the sensitivity function, S(s), and the transfer function from r to y is the complementary sensitivity function, T (s). The transfer function n → y is −T (s) In this case, the drug is administered to the patient through a syringe that is commanded by a computer that runs the controller algorithm, sampling the BIS index value every 5 seconds.
In this paper, an approach of the H ∞ optimal control design technique [17] is used to design an adequate controller for the problem at hand. The goal is to obtain a controller able to provide robust performance and robust stability, in the presence of model uncertainty, load disturbances and sensor noise. This controller is designed based on a class of 20 models, G = {G i , i = 1, 2, ..., 20}, obtained from patients subject to sedation.
Under these circumstances, input disturbance rejection and high frequency sensor noise rejection are problems to take into account in the control design, as well as the problem of zero steady-state tracking error, that is accomplished with the inclusion of an integral term.
Robust stability
The stability of the controlled system is the main goal in this work and, though performance is very important, one has to ensure that the patient DoA is stabilized by the controller. Therefore, for robust stability, the goal is to synthesize a stabilizing controller for all the models in the given class, G = {G i , i = 1, 2, ..., 20}, referred as patient model bank. For this sake, it is assumed that the true model G(s) of a given patient can be written as a function of a nominal model G N (s) as
where ∆ is the multiplicative uncertainty at frequency ω. In Fig. 3 , the frequency response of the models G i shows that there is a wide range of dynamic behaviors within these models. This high variability in the dynamic behaviors is a major difficulty in the design of a suitable controller for all the models. To obtain the best possible controller in terms of performance, two models are not used for controller design (models G 4 and G 14 ), being treated separately.
From the Nyquist stability criterion, it can be inferred that the controller K, that is designed to stabilize the nominal model G N , also stabilizes G if the following robust stability condition holds 
With (15), condition (16) can be written in the form
Let l(ω) be an upper bound function of the multiplicative uncertainty, meaning that
If l(ω) is such that
condition (16) is thus satisfied, and all the models that verify (19) will be stabilized by the controller K. Condition (19) may be written in the form
where T N is the complementary sensitivity function of the nominal model coupled with the controller and corresponds to the closed-loop transfer function. Therefore, if an upper bound function l(ω) for the multiplicative uncertainties exists such that its inverse is also an upper bound for the complementary sensitivity function, the controller designed for the nominal model has robust stability, meaning that all the systems G i that satisfy (19) are stabilized by the nominal controller.
Robust performance
In terms of performance, the controller is expected to be robust, being designed to reject load disturbances and high frequency sensor noise, in the presence of model uncertainty.
Following [17] , the load disturbance rejection objective is defined as a weighted sensitivity minimization problem and the measurement noise rejection objective is defined as a weighted complementary sensitivity minimization problem. These two goals are closely related through the specification of the controlled system bandwidth (by the sensitivity function) and reference tracking and robust stability specifications (related to the complementary sensitivity function).
In order to tackle the above minimization problems, two weighting functions are incorporated in the system, as depicted in Fig. 4 . In this case, W S and W T affect the sensitivity and the complementary sensitivity functions, respectively, and the closedloop system is
Since, for performance purposes of rejecting load disturbances, the gain of the weighted sensitivity function must be kept below 1, then it must be
where S is the sensitivity function given by
This weighted sensitivity function enforces the desired bandwidth while the weighted complementary sensitivity function enforces the adequate roll-off outside the bandwidth in which the disturbances are rejected. The noise rejection problem is approached in the same way, as the gain of the weighted complementary sensitivity function must be kept below 1, so that
where T is the complementary sensitivity function given by
Conditions (22) and (24) 
Controller analysis
With all the performance and robust stability specification taken into account, the controller synthesis is performed by using the DK algorithm for µ-synthesis [17] , in the implementation provided by the function dksyn of MATLAB R ⃝ , described by Robust Control Toolbox TM User's Guide [3] .
The controller takes the form of a state-space model and is designed for the nominal model G 15 , with the W S and W T of Fig. 5 , being described by
where A, B and C are the matrices that result from the design algorithm, e is the tracking error, e = r − y m , and x c is the controller state.
Stability analysis
Closed-loop stability can be checked by analyzing the loop-gain frequency response. Therefore, the closed-loop is stable if |KG( jω)| < 1 at the frequency ω for which ∠KG( jω) = −180
• .
The loop-gain response of all models of the patient model bank is shown in Fig. 6 , where the stability condition is proved to be fulfilled. To verify if the controller is able to stabilize all the models, one has to check the existence of an upper bound function l(ω) that yields conditions (19) and (20). These conditions are proved to be verified for the function l(ω) = (0.98s+0.010)/(s+0.0106), in Fig. 7 and Fig. 8 . The frequency responses of l(ω), in Fig. 7 , and of l −1 (ω), in Fig.  8 , show that this controller is robustly stable except for the models excluded from the design (G 4 and G 14 ). 
Performance analysis
The performance specifications imposed for the controller design are now checked. The performance condition described as weighted sensitivity minimization problem and defined in condition (22) is fulfilled for all the models except for model G 2 , as shown in Fig. 9 . The results of the weighted complementary sensitivity minimization problem are T . The time response to a step reference of 5 random models, in continuous time, is depicted in Fig. 10 showing that the controller provides an adequate control action in order to maintain the patient model at the desired level of DoA.
In spite of the controller not being able to a priori guarantee stability for models G 4 and G 14 , the time response of the controller with model G 4 (Fig. 10) shows that the controller is able to provide an acceptable performance. A similar situation holds for G 14 
Computer application
For computer application, the 21 st -order controller that directly results from the µ-synthesis design procedures is approximated by a lower order of 5. The order reduction is performed without the integral term for which the controller of order 20 is reduced to a 4 th -order. As shown by the Hankel singular value plot of the controller state-space representation, depicted in Fig. 11 , the majority of the system modes is well preserved in the 4 th -order controller. The integral action is then added. To prove that this order reduction is adequate, the loop-gain frequency response of the nominal model is compared with the full order controller, in Fig. 12 .
The sensitivity function and the complementary sensitivity function of the reducedorder controller are also compared in Fig. 13 with the ones of the full order controller. This comparison shows a very good agreement between both controllers in the frequency range of interest. This fact, as well as the agreement of time response, shown in Fig. 14 , justifies the use of the reduced complexity controller. reduced and discrete controller is presented in Fig. 15 , and allows to conclude that the stability condition is still met for all the patient models. Time response of a few models (G 1 , G 2 , G 4 , G 8 and G N ) of the patient model bank with the discrete controller, of order 5, is presented in Fig. 16 . This data shows that the controller is able to provide acceptable performances in time response with all models. Although models G 4 and G 14 are excluded from the controller design, the controller presents a good performance when applied to these models, as is possible to see with the time response of model G 4 , in Fig. 16 . 
Conclusions
An approach to the robust control of DoA based on H ∞ design and µ-synthesis has been proposed and illustrated using a bank of patient model data. The approach consists in characterizing a multiplicative uncertainty model description for the patients, enlarging this model with an integrator to ensure zero steady-state tracking error, controller design using the DK-algorithm, controller order reduction, and controller redesign in discrete time to obtain a controller suitable to computer application.
The controller that is designed aiming at robust performance and stability is able to track the reference for all the models. The performance conditions are fulfilled for all the models except one for which its sensitivity function does not fall below the bound W
−1
S . This controller has robust stability for 18 of the 20 models, although the time responses for the two other models left out are considered clinically adequate. The fact that the bounds of performance are crossed is the cost for robust stability, that is the ultimate goal to achieve at the problem at hand. The order reduction and the a posteriori discretization allows computer application with appropriate frequency and time responses.
